Abstract #1158

Multi-modality molecular imaging with hyperpolarized [1-13C]pyruvate MRSI and 18FDG-PET of early tumor response to a novel TRAIL agonist (MEDI3039)

Richard L Hesketh¹, Jiazheng Wang¹, Alan J Wright¹, Maria Fala¹, Susana Ros¹, Jodi Miller¹, David Y Lewis^1,2, and Kevin M Brindle^1,3

¹CRUK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, ²CRUK Beatson Institute, Glasgow, United Kingdom, ³Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom

This study compared the capability of 3D magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized [1-¹³C]pyruvate metabolism and ¹⁸FDG-PET to detect early responses to a TRAIL agonist (Medimmune MEDI3039) in Colo205 colorectal cancer and MDA-MB-231 triple-negative breast cancer xenograft models expressing luciferase and mStrawberry fluorescent protein. 24 hours after treatment, bioluminescence and hyperpolarized lactate/pyruvate ratio decreased significantly in all treated animals, preceding decreases in tumor volume. Conversely, ¹⁸FDG-PET did not detect treatment response. This suggests that for some tumors hyperpolarized [1-¹³C]pyruvate may be an improvement on ¹⁸FDG-PET and RECIST for the early detection of treatment response.

This abstract and the presentation materials are available to members only; a login is required.

Join Here